Selvita Will Present New Data from Its PIM/FLT3 and MNK1/2 Oncology Programs during AACR Annual Meeting 2014
Selvita, the largest independent drug discovery company in Central and Eastern Europe, will present new data at poster s…
Selvita, the largest independent drug discovery company in Central and Eastern Europe, will present new data at poster s…
. - Momentum builds for therascreen® KRAS RGQ PCR Kit and Rotor-Gene Q MDx instrument - Clarient offers network of 2,…
. - U.S. submission of therascreen® EGFR RGQ PCR Kit is paired with FDA submission of afatinib, an investigational tyro…
SCIENION AG and GENOMICA S.A. Unipersonal, today announced the expansion of their strategic partnership. Both companies…
. - U.S. launch of therascreen® KRAS RGQ PCR Kit offers enhanced approach to guide treatments for approximately 110,000…
. - therascreen® EGFR Mutation Detection Kit RGQ approved in Japan, one of the leading markets for pairing diagnostics…
. - Licenses diagnostic rights for ALK (anaplastic lymphoma kinase) gene, a promising target for novel class of lung ca…
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today launched its novel QIAsymphony RGQ system. The automated…
Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) announced positive test results today from a series of anim…
QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) today announced the results of operations for the fourth quar…